BCR and neoplasm: Furthermore, the levels of BCR/ABL protein, phospho-BCR/ABL and downstream molecules were significantly lower in co-treated tumor than in tumors treated with JNJ-165 or PD180970 (Figure 6C), which may contribute to combination therapy cytotoxicity.